(Q54622678)

1 June 2018

title

Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease. (English)

1 reference

1 June 2018

1 reference

1 reference

5

1 reference

1 June 2018

author name string

Yue Yong

1

1 reference

1 June 2018

Hanqing Ding

2

1 reference

1 June 2018

Zhiqin Fan

3

1 reference

1 June 2018

Jia Luo

4

1 reference

1 June 2018

publication date

4 January 2011

1 reference

1 June 2018

published in

Neurochemical Research

1 reference

1 June 2018

volume

36

1 reference

1 June 2018

issue

3

1 reference

1 June 2018

page(s)

367-374

1 reference

1 June 2018

Drug selection and timing of initiation of treatment in early Parkinson's disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Lithium delays progression of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Glycogen synthase kinase 3: a drug target for CNS therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

GSK3beta in ethanol neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

The 6-hydroxydopamine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Parkinson's disease: mechanisms and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Activation of double-stranded RNA-activated protein kinase by mild impairment of oxidative metabolism in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Reversal of thiamine deficiency-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Overexpression of glycogen synthase kinase 3beta sensitizes neuronal cells to ethanol toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-010-0368-Z

GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?

21 January 2018

1 reference

12 December 2020

Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death

1 reference

12 December 2020

Modeling Parkinson's disease

1 reference

12 December 2020

Lithium neuroprotection: molecular mechanisms and clinical implications

1 reference

12 December 2020

Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion

1 reference

12 December 2020

10.1007/S11064-010-0368-Z

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018